J&J Sets Erleada On RealTime Pathway For CastrationSensitive Prostate Cancer Claim

J&J Sets Erleada On Real-Time Pathway For Castration-Sensitive Prostate Cancer Claim

20:45 EDT 14 May 2019 | SCRIP

Erleada is ninth product known to be using US FDA’s Real-Time Oncology Review pilot program, as shown in our comprehensive...